en · de · es · fr · pt
cjc-1295-notes.peptides4962.com › Blog › Molecular Background And Naming — Research Overview

Molecular Background And Naming — Research Overview

By Editorial Desk · published 2025-09-12 · last reviewed 2025-10-27 · Blog

A practical reference on peptide mapping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-10-27 and is reviewed periodically as new material appears.

Molecular Background and Naming

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

Analytical Characterization and Storage

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.

Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight (no linker)~3.37 kDaCalculated from peptide sequence
Molecular weight (with linker)~3.65 kDaIncludes albumin-binding moiety
AppearanceWhite to off-white powderTypically lyophilized
SolubilitySoluble in waterAlso dissolves in aqueous buffers
Common synonymsModified GRF(1-29), DAC:GRFUsage varies by source

Albumin Binding and Duration of Action

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Related pages on this site

Persistence, Stability and Measurement

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Supporting material

Simon and Schuster. ISBN 978-1-4262-2005-0. Archived from the original on January 8, 2023. Retrieved January 8, 2023. Gainor, Chris (2001). Arrows to the Moon: Avro's Engineers and the Space Race. Burlington, Ontario: Apogee Books. ISBN 1-896522-83-1. Archived from the original on July 23, 2008. Retrieved August 2, 2019. Gatland, Kenneth (1976). Manned Spacecraft, Second Revision. New York: Macmillan Publishing Co., Inc. ISBN 0-02-542820-9. Hall, Rex; Shayler, David J. (2001). The Rocket Men: Vostok & Voskhod, The First Soviet Manned Spaceflights. New York: Springer–Praxis Books. ISBN 1-85233-391-X. Hall, Rex; Shayler, David J. (2003). Soyuz: A Universal Spacecraft. New York: Springer–Praxis Books. ISBN 1-85233-657-9. Hardesty, Von; Eisman, Gene (2007). Epic Rivalry: The Inside Story of the Soviet and American Space Race. Foreword by Sergei Khrushchev. Washington: National Geographic Society. ISBN 978-1-4262-0119-6. Harford, James J. (1997). Korolev: How One Man Masterminded the Soviet Drive to Beat America to the Moon (1 ed.). New York: John Wiley & Sons. ISBN 0-471-14853-9. Hepplewhite, T.A. (1999). The Space Shuttle Decision: NASA's Search for a Reusable Space Vehicle. Washington, DC: NASA. Jones, Eric M. (January 1, 2010). "Apollo 11 Lunar Surface Journal". Apollo Lunar Surface Journal. Internet. Archived from the original on January 16, 2012. Retrieved August 15, 2010. Kraft, Christopher C. (2001). Flight: My Life in Mission Control. New York: Dutton. ISBN 0-525-94571-7. Murray, Charles; Cox, Catherine Bly (1990). Apollo: The Race to the Moon.

Pakistan is considered a middle power nation, with the world's seventh-largest standing armed forces in terms of personnel size, comprising approximately 660,000 active-duty troops and 291,000 paramilitary personnel as of 2024. Established in 1947, the armed forces of Pakistan wielded significant influence over national politics. The main branches include the Army, Navy, and Air Force, supported by numerous paramilitaries. The Chairman of the Joint Chiefs of Staff Committee (CJCSC) is the highest-ranking military officer, advising the civilian government. However, they lack direct command over the branches and serve as intermediaries, ensuring communication between the military and civilian leadership. Overseeing the Joint Staff Headquarters, they coordinate inter-service cooperation and joint military missions. Command and control over Pakistan's strategic arsenal development and employment is vested in the National Command Authority, overseeing work on nuclear doctrine to maintain Full spectrum deterrence. The United States, Turkey, and China maintain close military relations with Pakistan Armed Forces, regularly exporting military equipment and technology transfer. Pakistan was the 5th-largest recipient and importer of arms between 2019 and 2023.

=== Others === In December 2025, Maduro asked Colombian society, including Colombia's army, to join in defending against any aggression from the US. Gustavo Petro, the president of Colombia, denied the request, stating that no one can order Colombia's armed forces, and later adding that Maduro was a dictator but not a narco-trafficker. Petro has called for a negotiated settlement.

The mild acidic and chemoselective post Ugi activation of 5 involving simultaneous indolamide formation and tert-butoxycarbonyl (Boc) removal gives the active amide 6 which allows cyclization to 7 without affecting other peptidic or even ester moieties and with stereochemical retention of the chiral centers.

== Example families == The peptide families in this section are ribosomal peptides, usually with hormonal activity. All of these peptides are synthesized by cells as longer "propeptides" or "proproteins" and truncated prior to exiting the cell. They are released into the bloodstream where they perform their signaling functions.

Sources: en.wikipedia.org

Supporting material

=== Lawsuits === In the late 1980s, Barker accused the American Humane Society and the United Activists for Animal Rights of condoning animal cruelty on the set of Project X and in several other media projects on the basis of allowing a cattle prod and a gun on set, and a rumored beating of a chimpanzee on set. American Humane responded by suing Barker for $10 million, citing libel, slander and invasion of privacy. American Humane claimed that there had been a two-year "vendetta" against them behind the accusations. In a series of public advertisements along with the lawsuit, American Humane responded to Barker's claims that his allegations were made based on insufficient and misleading information. The suit was eventually settled by Barker's insurance company, which paid American Humane $300,000. In 1994, former model Dian Parkinson filed a lawsuit against Barker alleging sexual harassment following a three-year affair while working on The Price Is Right. Parkinson, who alleged that she was extorted by threats of firing, later dropped her lawsuit, claiming the stress from the ordeal was damaging her health. In 1995, model Holly Hallstrom left The Price Is Right and later filed suit against Barker, alleging that the reason she was fired was not so much because of her 14-pound (6.4 kg) medication-mediated weight gain (as documented) but because, to Barker's displeasure, she refused to give false information to the media regarding Parkinson's suit, as she alleges Barker had requested she do.

== Additional facts == On Malacards, it has an information score of 7/100. There are currently no known genes or related disorders related to chondronectins. There are no current therapeutics, variations, expressions, pathways, GO terms or genetic tests for chondronectins currently. Chondronectin has been described as a trimeric glycoprotein with compact globular properties. The protein has most commonly been detected in cartilage related fluids such as synovial fluid and plasma. Chondronectin functions primarily as an attachment factor between chondrocytes and collagen based matrix materials. Most currently available information on chondronectin comes from isolation and characterization studies completed during the 1980s.

However, new kits such as "NETSPOT" for more rapidly preparing Ga-68 edotreotide or DOTATATE from Ga-68(III) ions have increased the flexibility of sourcing of this radiopharmaceutical for Ga-68 endocrine receptor (octreotide) scans. With NETSPOT the preparation of the Ga-68 DOTATATE is immediate once the Ga-68 has been acquired from the generator and mixed with the reagent.

=== Mechanism of liver injury === The cause of the mild, transient serum enzyme elevations during imipenem-cilastatin therapy is not known. The cholestatic hepatitis attributed to imipenem-cilastatin and the carbapenems is probably immunoallergic and resembles the rare, clinically apparent liver injury that has been linked to penicillins and cephalosporins.

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 a natural hormone?

No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.

Why do two versions share one name?

Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.

What is the relationship to GRF(1-29)?

The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.

How is sample identity confirmed?

Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.

Network